Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lisaftoclax by Ascentage Pharma Group International for Refractory Multiple Myeloma: Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Refractory Multiple Myeloma. According...
Lisaftoclax by Ascentage Pharma Group International for Relapsed Multiple Myeloma: Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Relapsed Multiple Myeloma. According...
Lisaftoclax by Ascentage Pharma Group International for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase III for Chronic Lymphocytic Leukemia (CLL)....
Lisaftoclax by Ascentage Pharma Group International for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Acute Myelocytic Leukemia (AML,...
Lisaftoclax by Ascentage Pharma Group International for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase I for Multiple Myeloma (Kahler Disease)....
Lisaftoclax by Ascentage Pharma Group International for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Human Epidermal Growth Factor...
Lisaftoclax by Ascentage Pharma Group International for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Chronic Myelocytic Leukemia (CML,...
Lisaftoclax by Ascentage Pharma Group International for Solid Tumor: Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Solid Tumor. According to...
Lisaftoclax by Ascentage Pharma Group International for Myelodysplastic Syndrome: Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Myelodysplastic Syndrome. According to...
Lisaftoclax by Ascentage Pharma Group International for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)....
Lisaftoclax by Ascentage Pharma Group International for Primary Systemic Amyloidosis: Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Primary Systemic Amyloidosis. According...
Lisaftoclax by Ascentage Pharma Group International for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase III for Chronic Lymphocytic Leukemia (CLL)....
Lisaftoclax by Ascentage Pharma Group International for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Acute Myelocytic Leukemia (AML,...